Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial-Reference-Cited by-同舟云学术

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

Published:2013-03 Issue:3 Volume:14 Page:228-235
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Robertson John FR,Ferrero Jean-Marc,Bourgeois Hugues,Kennecke Hagen,de Boer Richard H,Jacot William,McGreivy Jesse,Suzuki Samuel,Zhu Min,McCaffery Ian,Loh Elwyn,Gansert Jennifer L,Kaufman Peter A

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

2. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies;Yang;J Natl Cancer Inst,2011

3. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions;Hurvitz;Cancer,2008

4. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma;Bonneterre;Cancer,2001

5. Letrozole in advanced breast cancer: the PO25 trial;Mouridsen;Breast Cancer Res Treat,2007

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decoding the Role of Insulin-like Growth Factor 1 and Its Isoforms in Breast Cancer;International Journal of Molecular Sciences;2024-08-27

2. Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: Advances and opportunities;Biomedicine & Pharmacotherapy;2024-06

3. Insulin promotes growth in breast cancer cells through the type I IGF receptor in insulin receptor deficient cells;Experimental Cell Research;2024-01

4. Novel Therapies and Emerging Actives for Treatment of Luminal Breast Cancer;Research Journal of Pharmacy and Technology;2023-11-30

5. IGF-1R targeting in cancer – does sub-cellular localization matter?;Journal of Experimental & Clinical Cancer Research;2023-10-20